OBJECTIVE: To investigate the value of iodine-123 meta-iodobenzylguanidine (MIBG) myocardial imaging for defining high risk patients with idiopathic dilated cardiomyopathy from among candidates for beta blocker treatment, and for predicting functional improvement of the left ventricle in the early stages of treatment. METHODS: Echocardiographic indices, neurohormonal measurements, and myocardial MIBG distribution were assessed at baseline and after one month and three months of treatment in 27 patients with idiopathic dilated cardiomyopathy. Patients were classified into two groups, based on whether they reached a daily dose of > 20 mg of metoprolol without deterioration of heart failure at three months (group A, n = 20) or not (group B, n = 7). RESULTS: There were no significant differences in the echocardiographic indices or neurohormonal activity at baseline between the two groups, but MIBG uptake was higher, and the washout rate lower, in group A than in group B. After one month, though there were no significant changes in echocardiographic and neurohormonal variables, the heart to mediastinal (H/M) ratio on the delayed image was increased in group A but not in group B. In group A, the degree of increase in the H/M ratio on the delayed image after one month was also correlated with the degree of reduction in plasma concentrations of noradrenaline after three months. CONCLUSIONS: MIBG myocardial imaging may be useful for predicting the outcome of beta blocker treatment for heart failure patients with idiopathic dilated cardiomyopathy.
OBJECTIVE: To investigate the value of iodine-123 meta-iodobenzylguanidine (MIBG) myocardial imaging for defining high risk patients with idiopathic dilated cardiomyopathy from among candidates for beta blocker treatment, and for predicting functional improvement of the left ventricle in the early stages of treatment. METHODS: Echocardiographic indices, neurohormonal measurements, and myocardial MIBG distribution were assessed at baseline and after one month and three months of treatment in 27 patients with idiopathic dilated cardiomyopathy. Patients were classified into two groups, based on whether they reached a daily dose of > 20 mg of metoprolol without deterioration of heart failure at three months (group A, n = 20) or not (group B, n = 7). RESULTS: There were no significant differences in the echocardiographic indices or neurohormonal activity at baseline between the two groups, but MIBG uptake was higher, and the washout rate lower, in group A than in group B. After one month, though there were no significant changes in echocardiographic and neurohormonal variables, the heart to mediastinal (H/M) ratio on the delayed image was increased in group A but not in group B. In group A, the degree of increase in the H/M ratio on the delayed image after one month was also correlated with the degree of reduction in plasma concentrations of noradrenaline after three months. CONCLUSIONS:MIBG myocardial imaging may be useful for predicting the outcome of beta blocker treatment for heart failurepatients with idiopathic dilated cardiomyopathy.
Authors: P Merlet; H Valette; J L Dubois-Randé; D Moyse; D Duboc; P Dove; M H Bourguignon; C Benvenuti; A M Duval; D Agostini Journal: J Nucl Med Date: 1992-04 Impact factor: 10.057
Authors: J L Anderson; E M Gilbert; J B O'Connell; D Renlund; F Yanowitz; M Murray; M Roskelley; P Mealey; K Volkman; D Deitchman Journal: J Am Coll Cardiol Date: 1991-05 Impact factor: 24.094
Authors: E B Henderson; J K Kahn; J R Corbett; D E Jansen; J J Pippin; P Kulkarni; V Ugolini; M S Akers; C Hansen; L M Buja Journal: Circulation Date: 1988-11 Impact factor: 29.690
Authors: E J Eichhorn; J B Bedotto; C R Malloy; B A Hatfield; D Deitchman; M Brown; J E Willard; P A Grayburn Journal: Circulation Date: 1990-08 Impact factor: 29.690
Authors: Ji Chen; Russell D Folks; Liudmila Verdes; Daya N Manatunga; Arnold F Jacobson; Ernest V Garcia Journal: J Nucl Cardiol Date: 2011-12-07 Impact factor: 5.952
Authors: Maureen M Henneman; Frank M Bengel; Ernst E van der Wall; Juhani Knuuti; Jeroen J Bax Journal: J Nucl Cardiol Date: 2008-04-16 Impact factor: 5.952
Authors: F I Parthenakis; V K Prassopoulos; S I Koukouraki; E A Zacharis; G F Diakakis; N K Karkavitsas; P E Vardas Journal: J Nucl Cardiol Date: 2002 Jan-Feb Impact factor: 5.952